Author

R. Gerardy-Schahn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Klippert· 1 shared A. Muenster-Kuehnel· 1 shared A. Obenauf· 1 shared A.-K. Jochum· 1 shared B. Roshani· 1 shared C. B. Karsten· 1 shared C. Stahl-Hennig· 1 shared D. Hoffmann· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Klippert

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity

C. B. Karsten, F. F. R. Buttner, S. Cajic, I. Nehlmeier, B. Roshani, A. Klippert, U. Sauermann, N. Stolte-Leeb, U. Reichl, R. Gerardy-Schahn, E. Rapp, C. Stahl-Hennig, S. Pohlmann

This study compares glycosylation, infectivity, and neutralization sensitivity of SIV produced in macrophages versus CD4+ T cells, revealing differences in glycan profiles and their impact on viral spread and antibody neutralization.

bioRxiv · Jan 2, 2024Microbiology

Tumor sialylation controls effective anti-cancer immunity in breast cancer

S. Mereiter, G. Jonsson, T. Oliveira, J. Helm, D. Hoffmann, M. Abeln, A.-K. Jochum, W. Jochum, M. J. Kellner, M. Feith, V. Tkalec, K. Wasilewska, J. Jiao, L. Emsenhuber, F. Holstein, , J. M. Penninger

This study shows that tumor sialylation suppresses anti-cancer immunity in breast cancer by altering immune cell interactions and checkpoint ligands, and that inhibiting sialylation enhances immune response and therapy effectiveness.

bioRxiv · Sep 20, 2023 · PreprintCancer Biology